Jagsonpal Pharmaceuticals Ltd vs Procter Gamble Health Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Jagsonpal Pharmaceuticals Ltd is ₹ 209.5 as of 06 May 15:30 . The p/e ratio of Jagsonpal Pharmaceuticals Ltd changed from 25.9 to 32.9 over 5 quarters. This represents a CAGR of 21.09% The p/e ratio of Procter & Gamble Health Ltd changed from 52.5 to 0 over 9 quarters. This represents a CAGR of -100.00% The market cap of Jagsonpal Pharmaceuticals Ltd changed from ₹ 1433 crore to ₹ 743.27 crore over 5 quarters. This represents a CAGR of -40.88% The market cap of Procter & Gamble Health Ltd changed from ₹ 9285 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00% The revenue of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 67.37 crore as compare to the Dec '25 revenue of ₹ 75.92 crore. This represent the decline of -11.26% The revenue of Procter & Gamble Health Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 378.22 crore. This represent the decline of -100% The ebitda of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 14.33 crore as compare to the Dec '25 ebitda of ₹ 17.16 crore. This represent the decline of -16.49% The ebitda of Procter & Gamble Health Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 114.82 crore. This represent the decline of -100% The net profit of Jagsonpal Pharmaceuticals Ltd changed from ₹ 31.99 crore to ₹ 8.76 crore over 8 quarters. This represents a CAGR of -47.67% The net profit of Procter & Gamble Health Ltd changed from ₹ 46.56 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The dividend payout of Jagsonpal Pharmaceuticals Ltd changed from 29.99 % to 58.86 % over 5 quarters. This represents a CAGR of 71.50% The dividend payout of Procter & Gamble Health Ltd changed from 122.06 % to 0 % over 9 quarters. This represents a CAGR of -100.00% .

About Jagsonpal Pharmaceuticals Ltd

Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana.
The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs.
Simultaneously, it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India.
It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product.
In 1994, the company has also promoted Aresco Financial Services, a new financial company.

About Procter & Gamble Health Ltd

Procter & Gamble Health Limited was erstwhile incorporated as E Merck (India) Limited in 1967.
The Company's name was changed from E Merck (India) Limited to Merck Limited on March 27, 2002.
Later, the name of the Company was changed to Procter & Gamble Health Limited on 6 May, 2019.
The company was set up to take over the business of the Indian branch of Emeda Exports with all their assets and liabilities.
The company is a 51% subsidiary of German firm Merck KGaA, is a leading player in vitamin formulations. Procter & Gamble Health Limited is an Indian-based company principally engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.

FAQs for the comparison of Jagsonpal Pharmaceuticals Ltd and Procter & Gamble Health Ltd

Which company has a larger market capitalization, Jagsonpal Pharmaceuticals Ltd or Procter & Gamble Health Ltd?

Market cap of Jagsonpal Pharmaceuticals Ltd is 1,406 Cr while Market cap of Procter & Gamble Health Ltd is 8,854 Cr

What are the key factors driving the stock performance of Jagsonpal Pharmaceuticals Ltd and Procter & Gamble Health Ltd?

The stock performance of Jagsonpal Pharmaceuticals Ltd and Procter & Gamble Health Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Jagsonpal Pharmaceuticals Ltd and Procter & Gamble Health Ltd?

As of May 6, 2026, the Jagsonpal Pharmaceuticals Ltd stock price is INR ₹209.5. On the other hand, Procter & Gamble Health Ltd stock price is INR ₹5334.05.

How do dividend payouts of Jagsonpal Pharmaceuticals Ltd and Procter & Gamble Health Ltd compare?

To compare the dividend payouts of Jagsonpal Pharmaceuticals Ltd and Procter & Gamble Health Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.